Biomedical Engineering Reference
In-Depth Information
variable domains secreted from Escherichia coli. Nature 341,
544-546.
16. Jespers L, Schon O, Famm K, Winter G. (2004) Aggregation-
resistant domain antibodies selected on phage by heat dena-
turation. Nat. Biotechnol. 22, 1161-1165.
17. Jespers L, Schon O, James LC, Veprinstev D, Winter G. Crystal
Structure of HEL4, a soluble, refoldable human VH single
domain with a germ-line scaffold. J. Mol. Biol. 337, 893-903.
18. Ewert S, Cambillau C, Conrath K, Pluckthun A. (2002)
Biophysical properties of camelid VHH domains compared
to those of human VH3 domains. Biochemistry 41, 3628-3636.
19. Holt LJ, Basran A, Jones K, Chorlton J, Jespers L, Brewis ND,
et al. (2008) Anti-serum albumin domain antibodies for
extending the half-lives of short lived drugs. Protein Eng.
Des. Sel. 21, 283-288.
20. Walker A, Dunlevy G, Rycroft D, Topley P, Holt LJ, Herbert T,
et al. (2010) Anti-serum albumin domain antibodies in the
development of highly potent, efficacious and long-acting
interferon. Protein Eng. Des. Sel. 23, 271-278.
21. Durocher Y, Perret S, Kamen A. (2002) High-level and high-
throughput recombinant protein production by transient trans-
fection of suspension-growing human 293-EBNA1 cells.
Nucleic Acids Res. 2, E9.
22. Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L,
et al. (2008) Stable high volumetric production of glycosylated
human recombinant
29. Muyldermans S, Baral TN, Cortez Retamozzo V, De Baetselier
P, De Genst E, Kinne J, et al. (2009) Camelid immunoglobulins
and nanobody technology. Vet. Immunol. Immunopathol. 128,
178-183.
30. Muyldermans S, Lauwereys M. (1999) Unique single-domain
antigen binding fragments derived from naturally occurring
camel heavy-chain antibodies. J. Mol. Recognit. 12, 131-140.
31. Muyldermans S, Cambillau C, Wyns L. (2001) Recognition of
antigens by single-domain antibody fragments: The superflu-
ous luxury of paired domains. Trends Biochem. Sci. 26,
230-235.
32. De Genst E, Silence K, Decanniere K, Conrath K, Loris R,
Kinne J, et al. (2006) Molecular basis for the preferential cleft
recognition by dromedary heavy-chain antibodies. Proc. Natl.
Acad. Sci. USA 103, 4586-4591.
33. Nguyen VK, Desmyter A, Muyldermans S. (2001) Functional
heavy-chain antibodies in camelidae. Adv.
Immunol. 79,
261-296.
34. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M,
Dreier T, De Haard HJ, et al. (2008) Improved tumor targeting
of anti-epidermal growth factor receptor Nanobodies through
albumin binding: taking advantage of modular Nanobody
technology. Mol. Cancer Ther. 7, 2288-2297.
35. Dennis MS, Zhang M, Meng G, Kadkhodayan M, Kirchhofer
D, Combs D, et al. (2002) Albumin binding as a general
strategy for improving the pharmacokinetics of proteins. J.
Biol. Chem. 277, 35035-35043.
36. Dennis MS, Jin H, Dugger D, Yang R, McFarland L, Ogasa-
wara A, et al. (2007) Imaging tumors with an albumin-binding
Fab, a novel tumor-targeting agent. Cancer Res. 67, 255-261.
37. Nguyen A, Reyes AE, Zhang M, McDonald P, Wong WL,
Damico LA, et al. (2006) The pharmacokinetics of an albumin-
binding Fab (AB.Fab) can be modulated as a function of
affinity for albumin. Protein Eng. Des. Sel. 19, 291-297.
38. Dumelin CE, Trussel S, Buller F, Trachsel E, Bootz F, Zhang Y,
et al. (2008) A portable albumin binder from a DNA-encoded
chemical library. Angew. Chem. Int. Ed. 47, 3196-3201.
39. Trussel S, Dumelin C, Frey K, Villa A, Buller F, Neri D. (2009)
New strategy for the extension of the serum half-life of anti-
body fragments. Bioconjug. Chem. 20, 2286-2292.
40. Constantinou A, Epenetos AA, Hrezcuk-Hirst D, Jain S,
Deonarain MP. (2008) Modulation of antibody pharmaco-
kinetics by chemical polysialylation. Bioconjug. Chem. 19,
643-650.
41. Constantinou A, Chen C, Deonarain MP. (2010) Modulating
the pharmacokinetics of therapeutic antibodies. Biotechnol.
Lett. 32, 609-622.
42. Schellenberger V, Wang C, Geething NC, Spink BJ, Campbell
A, To W, et al. (2009) A recombinant polypeptide extends the
in vivo half-life of peptides and proteins in a tunable manner.
Nat. Biotechnol. 27, 1186-1192.
IFNalpha2b in HEK293 cells. BMC
Biotechnol. 8, 1-16.
23. Nilson BHK, Solomon A, Bjorck L, A
kerstrom B. (1992)
Protein L from Peptostreptococcus magnus binds to the
k
light chain variable domain. J. Biol. Chem. 267, 2234-2239.
24. Jankowski WJ, Von Muenchhausen W, Sulkowski E, Carter
WA. (1976) Binding of human interferons to immobilised
Cibacron blue F3GA: the nature of molecular interaction.
Biochemistry 15, 5182-5187.
25. Kassab A, Yavuz H, Odabasi M, Denizli A. (2000) Human
serum albumin chromatography by Cibacron Blue F3GA
derived microporous polyamide hollow-fiber affinity mem-
branes. J. Chromatogr. B 746, 123-132.
26. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M,
Hioki K, et al. (2002) NOD/SCID
g
c
null
mouse: an excellent
recipient mouse model for engraftment of human cells. Blood
100, 3175-3182.
27. Krepler C, Certa U, Wachek V, Jansen B, Wolf K, Pehamberger
H. (2004) Pegylated and conventional interferon-
a
induce
comparable transcriptional responses and inhibition of tumor
growth in a human melanoma SCID mouse xeno-
transplantation model. J. Invest. Dermatol. 123, 664-669.
28. Hamers-Casterman C, Atarhouch T, Muyldermans S,
Robinson G, Hamers C, Bajyana Songa E, et al. (1993)
Naturally occurring antibodies devoid of light chains. Nature
363, 446-448.
Search WWH ::
Custom Search